SYMBOL: 4138

DYNAMIC MEDICAL TECHNOLOGIES INC. -Investor Conference

DATE 2023/4/27



Disclaimer

This presentation is prepared according to the reviewed financial statements by CPA and the financial numbers hereby are based on IFRS, please refer to the published financial statements for full content.

The presentation may contain forward-looking information and may differ materially from the actual results. DMT does not warranty as to the accuracy or completeness of such information and nor assume any undertaking further information becomes available or in light of changing circumstances. You shall not place undue reliance on any for ward looking information.

The presentation and its contents may not be reproduced to a third party without the prior written consent of DMT.







1. 公司概況(Corporate Overview)



2. 市場概況(Market Overview)

3. 營運概況(Business Overview)

4. 財務概況(Financial Overview)

)5. 策略及展望(Strategies and Outlook)

— 6.行銷活動(Marketing)

)7. 補充資料(Appendix)





1. 公司概況(Corporate Overview)



Corporate Overview



傳輝東 Tony Fu

曜亞國際 •從台灣出發、『光曜亞洲、放眼國際』

經營理念


•客戶滿意・快樂員工・幸福企業 ・美麗人生



•誠信正直 團隊合作 當責創新



Top Provider of Medical Aesthetic Solutions in Asia







AREA	佳美 (EB)/ CYJ	Expand Business
North	17	6
Middle	3	1
South	5	0
Total	25	7

Expand Business











Market Overview

Medical aesthetic market can be divided into 4 sections: Energy-Based Device, Body Shaping and Skin Tightening, and Neurotoxin Dermal Filler, and DMT's distributed products covers all of the sections.


According to the Asian-Pacific Market Study issued by Medical Insight, Inc. in April. 2023, total Asian sales of all aesthetic products and equipment reached US\$4.4 billion in 2022 and the sales of Dermal Filler reached US\$2.2 billion.

Asian sales of aesthetic products expect grow 9.3%, from 2023 to 2027.





Taiwan Market Overview



Intensive Marketing prevail



Operating Superiority

Diversified facial injectables to satisfy comprehensive demands of aesthetic medicine market Complete aesthetic medicine consumable line, comprehensive one-stop beauty treatment The Company will continue to develop and introduce products that meet the latest and safe aesthetic medicine trends To make facial and body treatments more comprehensive and to provide superior services to consumers, the body sculpture treatment total solution






3. 營運概況(Business Overview)





DYNAMIC MEDICAL TECHNOLOGIES INC



DMT Revenue by product ratio

Unit : NTD\$K










4. 財務概況(Financial Overview)




Financial Overview


Unit : NTD\$K







Net Profit for the year







5. 策略及展望(Strategies and Outlook)



Future Prospects





Short-Term Planning

- ✓ DR.CYJ Channel Expansion
- ✓ Medytox Promote
- ✓ Southeast Asia Market Expansion
- Enhance the Sales of Aesthetic Consumables
- ✓ Best Salles Expansion

Mid-Term Planning

- ✓ Preventive Medicine
- Body Contouring Market Development
- ✓ Consumable Product Development

Long-Term Planning


- ✓ Brand diversification
- Medical beauty products market positioner
- ✓ Southeast Asia Market
 Strategic Alliance








DRCYJ







Channel Expansion







6.行銷活動(Marketing)



2022 ANNUAL MEETING of LMSTW







宗

2022 TSAPS INTERNATIONAL ANNUAL MEETING



The 48th Annual Meeting of Taiwanese Dermatological Association







講題: Max your daily practice : my clinical experience with GentleMax 座長:鄭國良 醫師(儲寶得皮膚科診所院長)—

😞 Dr. Peter Peng ≈ 🔵 GentleMax Pro*

🕜 曜亞國際股份有限公司



🚫 曜亞國際股份有

曜石風座

Medytox Introduction







Candela Expert Summit




◎曜亞國際





DYNAMIC MEDICAL TECHNOLOGIES IN 28

2022 Taiwanese Dermatological Association V1 V2 Camp









AestheFill & Animers Training







Medytox Training





Animers Comsulant's Course









CONSOLIDATED BALANCE SHEETS-1

Unit : NTD\$K	2019/12/31	2020/12/31	2021/12/31	2022/12/31
Cash and cash equivalents	681,226	784,901	813,371	679,126
Debt investments with no active market - current	468,649	447,351	492,091	581,456
Notes receivable & Trade receivables	166,001	134,837	133,539	183,476
Inventories	229,816	147,124	170,233	246,866
Other current assets	19,759	22,959	33,043	45,056
Total current assets	1,565,451	1,537,172	1,642,277	1,735,980
Long-term investment	150,449	152,721	132,655	243,308
Property, plant and equipment	134,894	114,499	136,013	213,141
Right-of-use asset	171,216	153,364	204,793	280,063
Other non-current assets	202,353	185,079	183,053	208,679
TOTAL	2,224,363	2,142,835	2,298,791	2,681,171



CONSOLIDATED BALANCE SHEETS-2

Unit : NTD\$K	2019/12/31	2020/12/31	2021/12/31	2022/12/31
Notes payable & Trade payables	58, 818	27, 101	61, 554	64,041
Other payables	185, 019	152, 170	134, 488	175, 275
contract liability	295, 460	306, 505	375, 255	481,076
Other current liabilities	81,208	69, 894	86, 258	155, 527
Total current liabilities	620, 505	555, 670	657, 555	875, 919
Other non-current liabilities	4, 294	5, 820	3, 172	20, 636
Lease liabilities – Non related parties	131, 353	118, 148	166, 141	230, 615
Total liabilities	756, 152	679, 638	826, 868	1, 127, 170
Ordinary shares	300, 000	300, 000	300, 000	300, 000
Retained earnings	303, 971	319, 580	337, 807	364, 414
Capital surplus	627, 726	627, 726	627, 726	627, 726
Other equity	50, 013	43, 624	18, 509	95, 586
NON-CONTROLLING INTERESTS	186, 501	172, 267	187, 881	166, 275
Total equity	1, 468, 211	1,463,197	1,471,923	1, 554, 001
TOTAL	2, 224, 363	2, 142, 835	2, 298, 791	2, 681, 171
The Net Asset Value of Each Share	48.94	48.77	49.06	51.80
				DYNAMIC MEDICAL TECHNOLOGIES INC.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

Unit: NTD\$K	2019年度 2020年度		2021年度		2022年度			
	AMT	%	AMT	%	AMT	%	AMT	%
OPERATING REVENUE	1,178,195	100.00	1,009,308	100.00	1,028,183	100.00	1,291,692	100.00
OPERATING COSTS	844,027	71.64	691,266	68.49	673,601	65.51	839,162	64.97
GROSS PROFIT	334,168	28.36	318,042	31.51	354,582	34.49	452,530	35.03
OPERATING EXPENSES	176,345	14.97	177,194	17.56	194,164	18.88	294,200	22.78
PROFIT FROM OPERATIONS	157,823	13.40	140,848	13.95	160,418	15.60	158,330	12.26
NON-OPERATING INCOME AND EXPENSES	2,152	0.18	7,842	0.78	13,403	1.30	19,832	1.54
PROFIT BEFORE INCOME TAX	159,975	13.58	148,690	14.73	173,821	16.91	178,162	13.79
INCOME TAX EXPENSE	33,903	2.88	32,048	3.18	32,132	3.13	38,301	2.97
NET PROFIT FOR THE YEAR	126,072	10.70	116,642	11.56	141,689	13.78	139,861	10.83
OTHER COMPREHENSIVE INCOME	(9,098)	(0.77)	(7,023)	(0.70)	(25,111)	(2.44)	77,477	6.00
TOTAL COMPREHENSIVE INCOME FOR THE YEAR	116,974	9.93	109,619	10.86	116,578	11.34	217,338	16.83
NET PROFIT ATTRIBUTABLE TO Owners of the Company	112,521	9.55	115,995	11.49	123,206	11.98	137,111	10.61
EPS	3.75		3.87		4.11			
							UTRAMIC	ILLINGAL ILLINGLOGI

CONSOLIDATED STATEMENTS OF CASH FLOW-1

Unit: NTD\$K	2019	2020	2021	2022
Cash flows from operating activities:				
Profit before tax	159,975	148,690	173,821	178,162
Total adjustments to reconcile profit	72,554	80,264	88,856	102,422
Accounts receivable	43,993	35,386	(5,416)	(60,444)
Other receivable	(457)	646	(29)	(425)
Inventories	78,140	63,893	(52,459)	(102,487)
Accounts payable	(21,036)	(31,717)	34,453	2,487
Other payable	(4,669)	(32,849)	(17,682)	40,787
Income taxes paid	(30,810)	(25,547)	(21,857)	(15,799)
Other	(30,733)	9,785	77,958	132,226
Net cash flows from operating activities	266,957	<u>248,551</u>	<u>277,645</u>	276,929



CONSOLIDATED STATEMENTS OF CASH FLOW-2

Unit: NTD\$K	2019	2020	2021	2022
Cash flows from investing activities:				
Acquisition of financial assets at amortised cost	(348,649)	(246,501)	(268,491)	(441,456)
Proceeds from disposal of financial assets at	60,000	267,799	223,751	352,091
amortised cost				
Increase in other financial assets	(7,000)	-	-	-
Decrease in refundable deposits	(3,139)	(1,890)	2,556	(5,845)
Dividends received	1,859	4,784	2,970	3,861
Other	(15,124)	(6,904)	(53,205)	(159,934)
Net cash flows from (used in) investing activities	(312,053)	17,288	<u>(92,419)</u>	(251,283)
Cash flows from financing activities:				
Cash dividends paid	(94,500)	(100,500)	(105,000)	(111,000)
Other	(43,417)	(50,943)	(43,680)	(75,862)
Net cash flows used in financing activities	(137,917)	<u>(151,443)</u>	<u>(148,680)</u>	(186,862)
Effect of exchange rate changes on cash and cash	(4,646)	(10,721)	(8,076)	26,971
equivalents				
Net (decrease) increase in cash and cash equivalents	(187,659)	103,675	28,470	(134,245)
Cash and cash equivalents at beginning of period	868,885	<u>681,226</u>	784,901	813,371
Cash and cash equivalents at end of period	681,226	784,901	813,371	679,126
			6	े. एस २५ स्थि

DYNAMIC MEDICAL TECH 38

Accumulated years of experience, DMT. is in the leading edge of the medical aesthetic market by means of sophisticated sales and marketing forces and dedicated service and management team. With successful integration, DMT has achieved vertical integration of medical aesthetics resources. From importing medical aesthetic products to assisting clinical operations, DMT has created global competitive advantage. We have already positioned ourselves in the Greater China market and will keep making all-out effort to enhance Greater China Medical Aesthetic market. The value created by DMT will be clear for all to see!







|國際尖端醫美儀器銷售 | 醫美儀器維修保養 | 植入式填充劑鎬售 | 整合性醫美行銷服務 | 專業健髮系統鎬售 |

International medical aesthetics equipment selling Medical aesthetics equipment maintenance Dermal filler selling Integrated marketing services for medical aesthetics Professional hair growth system selling



THANK YOU!